Last month, I published four posts to share with you my experience in using matplotlib. Benefit from its full control of elements on a given graph, matplotlib is deemed as a fundamental python library for data visualisation and used by many other libraries (e.g. seaborn and pandas) as plotting module. This is also why I think learning matplotlib is an essential part for being a practitioner in data science, which helps to build up in-depth understanding about logic behind data visualisation tools.
ATLANTA – LabLynx, Inc., long-time leader in enterprise-level cloud-hosted LIMS/LIS, today announced it has developed the world’s first LIMS (Laboratory Information Management System) dedicated specifically to COVID-19 diagnostic testing. Called "CovidLIMS”, its main features include, crucially, swift setup-to-live time: 2-5 days, including training, according to LabLynx President John H. Jones.
The novel SARS-CoV-2 virus and the disease it causes (COVID-19) are sweeping the world. The US’s ability to rapidly and accurately test patients, not to mention their health care providers, is critical to containing the virus. That said, it has proved to be one of the biggest challenges for our country in recent weeks. Much has already been written about what initially went wrong with the coronavirus testing in the US and why the US government and CDC lagged behind other developed nations in deploying diagnostics. This article will instead focus on the remarkable companies, institutions, and clinical labs that are rising to the challenge by working around the clock to produce high volumes of accurate and reliable tests. In addition to the COVID-19 tests that are already in use, companies are prototyping groundbreaking new diagnostics. These new tests have the potential to revolutionize COVID-19 detection now and chart the course for the future of infectious disease diagnostics.
The Pittcon 2020 roundup for those that didn't make there. Pittcon 2020, the annual laboratory science conference, had a very different feel to it this year. If the show had been held just two weeks later, with much of the USA and Europe in lock-down, it would not had gone ahead. Although the USA had not at that stage seen many cases of Coronavirus this was the word on everyone’s lips as they walked the exhibition hall and conference. Several booths were left empty with signs saying the exhibitor was “Absent due to travel restrictions”. Certainly the most popular thing on the Autoscribe stand were individual packets of antimicrobial hand wipes which we had bought along to give-away.
In the midst of the COVID-19 outbreak, the world is looking to the scientific community for help. We know that scientists everywhere are mobilizing to characterize the virus, to replicate and study it in lab, to perform testing and analyze results, to develop next-gen diagnostics, and to quickly develop vaccines and antiviral treatments. To support these efforts, we have set up a COVID-19 resources webpage that points to sequences, protocols, and other work that has been shared by scientists for public use. Our hope is that these resources will be beneficial to the greater scientific community, especially to scientists who are actively addressing this challenge. We are accepting submissions from scientists and will be updating the page regularly. You may share data in Benchling — protocols, sequences, experimental results. You may also share an existing resource with us — a pre-print, a published protocol. Please find instructions for contributing below.
One of the most common integration platforms used in laboratory informatics is Pipeline Pilot from BIOVIA. Whether part of a large enterprise software implementation or a project to pass data between two applications, integration projects always present challenges. In the laboratory environment, achieving integration goes beyond merely exchanging data between applications. Laboratory equipment/automation, specialized data sets, and validation complicate an already difficult task and create unique challenges. In addition to the goals of streamlining business operations, eliminating data silos and minimizing redundant data entry, integration also has to be done in such a way that supports regulatory compliance and promotes data integrity.
The final part of this series will focus on how QLIMS supports the manufacturing of medicinal cannabis products. The focus will be data management, final product formulations, compliance with GMP guidelines and workflow tracking.
Medicinal Cannabis Manufacturing
A large number of medicinal cannabis facilities set up across Australia are focused on manufacturing for local and exporting. As such the sampling numbers are going to be very high so a system to effectively manage all that data, maintain traceability and help keep compliant with GMP will be important.
As seen from our previous posts, no matter what data you are looking to record and track a LIMS can help.
In this brief editorial article published in the journal Diagnostics, Tiawanese researchers Yang et al. provide their insights into a more convenient at-home point-of-care (POC) testing method for the COVID-19 illness. Noting the urgency of the associated pandemic and the various costs associated with traditional testing methodologies such as lateral flow immunoassays and molecular-based assays, the authors suggest the blending of several tools: a paper-based result and common mobile devices. A patient at home could take a nasal swab and use a POC device to return a colorimetric result, which could then be captured by mobile phone and rapidly sent to a clinician for analysis. They conclude that such a method could "provide new insights into designing POC COVID-19 diagnostics and ultimately improve the health care system to combat this and similar diseases."
This is the third of a series of interim guidance documents, this one originating from the U.S. Food and Drug Administration (FDA). Issued on March 16, this guidance document provides insight into FDA policy for the development, validation, and use of diagnostic tests for Coronavirus Disease-2019 (COVID-19), particularly those tests issued an Emergency Use Authorization (EUA). This guidance applies to not only manufacturers developing and distributing test kits but also CLIA laboratories cleared for high-complexity testing that develop and validate their own tests. The FDA provides background on the topic and then discusses the policy in detail, before closing with its validation study recommendations.